Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.

Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL.

JAMA. 1993 Apr 21;269(15):1970-4. Erratum in: JAMA 1993 Aug 18;270(7):832.

PMID:
8352830
2.

Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.

Couch FJ, Garber J, Kiousis S, Calzone K, Hauser ER, Merajver SD, Frank TS, Boehnke M, Chamberlain JS, Collins FS, et al.

J Natl Cancer Inst Monogr. 1995;(17):9-14.

PMID:
8573462
3.

Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.

Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS, et al.

Clin Cancer Res. 1995 May;1(5):539-44.

4.

A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.

Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, Lynch HT, Feunteun J, Lenoir GM.

Am J Hum Genet. 1996 Jan;58(1):42-51.

5.

A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.

Goldgar DE, Fields P, Lewis CM, Tran TD, Cannon-Albright LA, Ward JH, Swensen J, Skolnick MH.

J Natl Cancer Inst. 1994 Feb 2;86(3):200-9.

PMID:
8283492
6.

Familial breast cancer. Approaching the isolation of a susceptibility gene.

Weber BL, Abel KJ, Brody LC, Flejter WL, Chandrasekharappa SC, Couch FJ, Merajver SD, Collins FS.

Cancer. 1994 Aug 1;74(3 Suppl):1013-20. Review.

7.

Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.

Essioux L, Girodet C, Sinilnikova O, Pagès S, Eisinger F, de Résende S, Maugard C, Lanoë D, Longy M, Bignon YJ, Sobol H, Bonaïti-Pellié C, Stoppa-Lyonnet D.

Am J Med Genet. 1998 Sep 23;79(3):175-83.

PMID:
9788557
8.

Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.

Bowcock AM.

Breast Cancer Res Treat. 1993 Nov;28(2):121-35. Review.

PMID:
8173065
9.

Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.

Chang-Claude J, Dong J, Schmidt S, Shayeghi M, Komitowski D, Becher H, Stratton MR, Royer-Pokora B.

J Med Genet. 1998 Feb;35(2):116-21.

10.

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

Johannsson O, Ostermeyer EA, Håkansson S, Friedman LS, Johansson U, Sellberg G, Brøndum-Nielsen K, Sele V, Olsson H, King MC, Borg A.

Am J Hum Genet. 1996 Mar;58(3):441-50.

11.

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR.

Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. Review.

PMID:
8828444
12.

[Risk assessment for familial occurrence of breast cancer].

Chang-Claude J, Becher H, Hamann U, Schroeder-Kurth T.

Zentralbl Gynakol. 1995;117(8):423-34. German.

PMID:
7571905
13.

[Experience at Sheba Hospital in oncogenetic counseling and genetic testing of women with a high risk for breast and ovarian cancer].

Theodor L, Shiri-Sverdlov R, Yechezkel GH, Bar-Sade RB, Gak E, Friedman I, Kruglikova A, Ben-Baruch G, Risel S, Papa MZ, Goldman B, Friedman E.

Harefuah. 1998 Apr 15;134(8):593-9, 672. Hebrew.

PMID:
10911419
14.

BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.

Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.

Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.

15.

German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.

Hamann U, Brauch H, Garvin AM, Bastert G, Scott RJ.

Genes Chromosomes Cancer. 1997 Feb;18(2):126-32.

PMID:
9115962
16.

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL.

N Engl J Med. 1997 May 15;336(20):1409-15.

17.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

18.

Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.

Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS, Tucker MA.

Am J Hum Genet. 1995 Jul;57(1):1-7.

19.

Linkage analysis of 26 Canadian breast and breast-ovarian cancer families.

Tonin P, Moslehi R, Green R, Rosen B, Cole D, Boyd N, Cutler C, Margolese R, Carter R, McGillivray B, et al.

Hum Genet. 1995 May;95(5):545-50.

PMID:
7759076
20.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

Supplemental Content

Support Center